hydroxyurea has been researched along with via 2291 in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (66.67) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basha, A; Bhatia, P; Bouska, JB; Brooks, CD; Craig, RA; Kolasa, T; Lanni, C; Martin, JG; Ratajczyk, JD; Stewart, AO | 1 |
| Bell, RL; Bouska, JB; Brooks, CD; Carter, GW; Harris, RR; Hulkower, KI; Malo, PE; Shaughnessy, TK | 1 |
| Carpentier, PJ; Drajesk, JF; Joos, GF; Kips, JC; Pauwels, RA; Van Schoor, J | 1 |
| Bell, RL; Harris, RR; Komater, VA; Marett, RA; Wilcox, DM | 1 |
| Awni, WM; Chang, M; Drajesk, J; Hansen, R; Lanni, C; Witt, G; Wong, SL | 1 |
| Awni, WM; Chang, MS; Drajesk, J; Witt, G; Wong, SL | 1 |
| Carpentier, PJ; Dent, G; Herst, RS; Lehnigk, B; Magnussen, H; Rabe, KF | 1 |
| Awni, WM; Dube, LM; O'Dea, RF; Wong, SL | 1 |
| Machinist, JM; Mayer, MD; Roberts, EM; Rodrigues, AD; Surber, BW | 1 |
| Awni, WM; Cavanaugh, JH; Hansen, R; Qian, J; Wong, SL | 1 |
| Ansell, J; Argentieri, DC; Beers, KN; Chen, RH; Connolly, PJ; Hamel, SC; Ritchie, DM; Singer, MM; Steber, M; Wachter, MP; Wetter, SK | 1 |
| Drajesk, J; Drazen, JM; Dubé, L; Hippensteel, R; Israel, E; Katz, DA; Pillari, A; Schork, N; Silverman, ES; Szczerback, N; Yandava, CN | 1 |
| Reid, JJ | 1 |
| Arthur, AS; Barbosa, MD; Gazak, C; Kassell, NF; Louis, RH; MacDonald, T; Polin, RS | 1 |
| Briskin, J; Fort, JJ; Gerhardt, AH; Mayer, P; Qiu, Y; Schilling, RJ; Trivedi, J | 1 |
| Brotz, TM; Cossette, M; Grégoire, JC; Ibrahim, R; Kouz, S; L'allier, PL; Lavoie, MA; Nozza, A; Paquin, J; Pressacco, J; Tardif, JC; Taub, R | 1 |
| Brotz, TM; Farkouh, M; Fayad, ZA; Gaztanaga, J; Kerwin, TC; Mani, V; Rosenbaum, D; Rudd, JH; Tardif, JC; Taub, R; Tawakol, A | 1 |
| Budoff, MJ; Grégoire, JC; Ibrahim, R; L'Allier, PL; Matsumoto, S; Pressacco, J; Tardif, JC | 1 |
10 trial(s) available for hydroxyurea and via 2291
| Article | Year |
|---|---|
The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects.
Topics: Adenosine; Adult; Asthma; Bronchi; Bronchial Provocation Tests; Bronchoconstriction; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Exercise; Female; Forced Expiratory Volume; Humans; Hydroxyurea; Leukotriene B4; Lipoxygenase Inhibitors; Male; Middle Aged; Vasodilator Agents | 1997 |
Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Reference Values | 1998 |
Dose-proportional pharmacokinetics of a new 5-lipoxygenase inhibitor, ABT-761, in healthy volunteers.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Placebos | 1998 |
Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients.
Topics: Adult; Asthma, Exercise-Induced; Bronchoconstriction; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Exercise Test; Female; Humans; Hydroxyurea; Leukotriene E4; Lipoxygenase Inhibitors; Male | 1998 |
Effects of ABT-761, a novel 5-lipoxygenase inhibitor, on the pharmacokinetics of a single dose of ethinyl estradiol and levonorgestrel in healthy female volunteers.
Topics: Adult; Contraceptive Agents, Female; Contraceptives, Oral; Drug Interactions; Estradiol Congeners; Ethinyl Estradiol; Female; Humans; Hydroxyurea; Levonorgestrel; Lipoxygenase Inhibitors | 1998 |
Lack of cytochrome P450 1A2 interaction effect of ABT-761 on the pharmacokinetics of theophylline.
Topics: Adult; Cytochrome P-450 CYP1A2; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Metabolic Clearance Rate; Theophylline | 1998 |
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.
Topics: Alleles; Anti-Asthmatic Agents; Arachidonate 5-Lipoxygenase; Asthma; Gene Frequency; Genetic Variation; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Phenotype; Promoter Regions, Genetic; Treatment Outcome | 1999 |
Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Analysis of Variance; Arachidonate 5-Lipoxygenase; Biomarkers; C-Reactive Protein; Contrast Media; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxyurea; Leukotriene B4; Leukotriene E4; Lipoxygenase Inhibitors; Male; Middle Aged; Observer Variation; Prospective Studies; Radiographic Image Enhancement; Tomography, X-Ray Computed; Treatment Outcome; Triiodobenzoic Acids | 2010 |
A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aortitis; Aortography; Canada; Carotid Artery Diseases; Double-Blind Method; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Middle Aged; Multidetector Computed Tomography; Multimodal Imaging; Positron-Emission Tomography; Predictive Value of Tests; Time Factors; Treatment Outcome; United States; Vasculitis | 2015 |
Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Computed Tomography Angiography; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Middle Aged; Multidetector Computed Tomography; Plaque, Atherosclerotic; Prospective Studies; Time Factors; Treatment Outcome | 2017 |
8 other study(ies) available for hydroxyurea and via 2291
| Article | Year |
|---|---|
(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
Topics: Animals; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Macaca fascicularis; Male; Microsomes, Liver; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship | 1995 |
ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents.
Topics: Animals; Bronchoconstriction; Enzyme Inhibitors; Eosinophils; Guinea Pigs; Humans; Hydroxyurea; In Vitro Techniques; Leukotriene E4; Lipoxygenase Inhibitors; Macaca fascicularis; Male; Mice; Muscle Contraction; Pneumonia; Rats | 1997 |
Effect of mast cell deficiency and leukotriene inhibition on the influx of eosinophils induced by eotaxin.
Topics: Animals; Chemokine CCL11; Chemokines, CC; Cytokines; Eosinophils; Hydroxyurea; Injections, Intraperitoneal; Leukotriene Antagonists; Leukotrienes; Lipoxygenase Inhibitors; Mast Cells; Mice; Mice, Inbred BALB C; Peritoneal Cavity | 1997 |
Identification of the human liver cytochrome P450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor.
Topics: Catalysis; Cytochrome P-450 Enzyme System; DNA, Complementary; Fluorobenzenes; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Microsomes, Liver; Thiophenes | 1998 |
N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase.
Topics: Animals; Cyclooxygenase Inhibitors; Dogs; Hydroxamic Acids; Hydroxyurea; In Vitro Techniques; Lipoxygenase Inhibitors | 1999 |
ABT-761 (Abbott).
Topics: Asthma; Clinical Trials, Phase III as Topic; Humans; Hydroxyurea; Lipoxygenase Inhibitors | 2001 |
The novel 5-lipoxygenase inhibitor ABT-761 attenuates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage.
Topics: Animals; Basilar Artery; Disease Models, Animal; Enzyme Inhibitors; Hydroxyurea; Lipoxygenase Inhibitors; Male; Rabbits; Subarachnoid Hemorrhage; Vasospasm, Intracranial | 2001 |
Effect of physicochemical and formulation variables on the in vivo absorption of ABT-761.
Topics: Absorption; Animals; Chemical Phenomena; Chemistry, Pharmaceutical; Chemistry, Physical; Dogs; Hydroxyurea | 2002 |